3.76

0.27% -0.01

Neuronetics Inc (STIM)

Overview News Price History Option Chain Financials Discussions Forecast

Neuronetics Inc stock is traded at $3.76, with a volume of 300.27K. It is down -0.27% in the last 24 hours and down -25.69% over the past month. Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Previous Close:

$3.77

Open:

$3.79

24h Volume:

300.27K

Relative Volume:

0.22

Market Cap:

$250.75M

Revenue:

$69.23M

Net Income/Loss:

$-33.10M

P/E Ratio:

-3.1864

EPS:

-1.18

Net Cash Flow:

$-39.26M

1W Performance:

-0.27%

1M Performance:

-25.69%

6M Performance:

+313.19%

1Y Performance:

-5.05%

1-Day Range:

$3.63

$3.8195

1-Week Range:

$3.60

$4.14

52-Week Range:

$0.52

$5.92

Neuronetics Inc Stock (STIM) Company Profile

Name

Neuronetics Inc

Sector

Healthcare (1151)

Industry

Diagnostics & Research (58)

Phone

877-600-7555

Address

3222 PHOENIXVILLE PIKE, MALVERN, PA

Employee

716

Twitter

@tmstherapy

Next Earnings Date

2025-03-04

Latest SEC Filings

STIM's Discussions on Twitter

Compare STIM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STIM Neuronetics Inc	3.76	250.75M	69.23M	-33.10M	-39.26M	-1.18
TMO Thermo Fisher Scientific Inc	427.50	169.62B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	186.83	138.06B	23.88B	3.90B	5.30B	5.28
IDXX Idexx Laboratories Inc	411.49	32.79B	3.90B	887.87M	798.08M	10.67
A Agilent Technologies Inc	102.48	29.99B	6.53B	1.26B	1.31B	4.35
IQV Iqvia Holdings Inc	143.91	26.61B	15.41B	1.37B	2.11B	7.50

Neuronetics Inc Stock (STIM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-13-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-13-21	Downgrade	BTIG Research	Buy → Neutral
Oct-13-21	Downgrade	William Blair	Outperform → Mkt Perform
Jan-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Feb-06-20	Initiated	BTIG Research	Buy
Jul-24-18	Initiated	Canaccord Genuity	Buy

View All

Neuronetics Inc Stock (STIM) Latest News

Apr 09, 2025

Neuronetics Reports 2024 Financial Results and Strategic Advances - MSN

Apr 09, 2025

Apr 08, 2025

Transcranial Magnetic Stimulator Market to Witness Remarkable - openPR.com

Apr 08, 2025

Apr 06, 2025

Neuronetics Announces Expanded Coverage for NeuroStar TMS to Treat Adolescent Depression - MSN

Apr 06, 2025

Apr 02, 2025

Even though Neuronetics (NASDAQ:STIM) has lost US$30m market cap in last 7 days, shareholders are still up 130% over 5 years - simplywall.st

Apr 02, 2025

Mar 31, 2025

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression - The Manila Times

Mar 31, 2025

Major Insurance Breakthrough: NeuroStar's Teen Depression Treatment Now Covered for 15 Million Lives - Stock Titan

Mar 31, 2025

Neuronetics Revises Financial Results for Q4 and Full Year 2024 - MSN

Mar 31, 2025

Mar 30, 2025

Neuronetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Mar 30, 2025

Mar 29, 2025

Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs (NASDAQ:STIM) - Seeking Alpha

Mar 29, 2025

Mar 28, 2025

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results - The Manila Times

Mar 28, 2025

Mar 27, 2025

Neuronetics Some Non-Cash Revisions Made To Financial Statements Related To Co's Acquisition Of Greenbrook Tms & Shares Outstanding In Q4 - Marketscreener.com

Mar 27, 2025

Neuronetics Updates Financial Results: Q4 Losses Deepen After Greenbrook Deal Review - Stock Titan

Mar 27, 2025

Mar 26, 2025

Transcranial Magnetic Stimulator Market Is Booming So Rapidly - openPR.com

Mar 26, 2025

Mar 25, 2025

This Penny Stock Is Up 170% in 2025 and Analysts Think It Can Rally Further From Here - The Globe and Mail

Mar 25, 2025

Mar 24, 2025

FDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder - MSN

Mar 24, 2025

Mar 23, 2025

While private equity firms own 38% of Neuronetics, Inc. (NASDAQ:STIM), retail investors are its largest shareholders with 43% ownership - Yahoo

Mar 23, 2025

Mar 18, 2025

Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet - Yahoo Finance

Mar 18, 2025

Mar 12, 2025